Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients ...

In the case of myasthenia gravis, the body produces autoantibodies that target acetylcholine receptors (AChRs), which are essential triggers for normal muscle contraction functions. Medications ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with ...

In the case of myasthenia gravis, the body produces autoantibodies that target acetylcholine receptors (AChRs), which are essential triggers for normal muscle contraction functions. Medications ...

Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis ...

score and 87% of the patients demonstrated a ≥ 5-point reduction in Quantitative Myasthenia Gravis (QMG) score at Week 24. With the highest MG-ADL response rate among all drugs for gMG with ...

Myasthenia Gravis [MG] is a type of an autoimmune disorder ... That's because there are no FDA approved drugs to treat this specific disorder. Not only that, but current treatment options only ...

With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health ...